Wall Street analysts expect that AngioDynamics, Inc. (NASDAQ:ANGO) will announce sales of $83.37 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for AngioDynamics’ earnings, with the lowest sales estimate coming in at $83.30 million and the highest estimate coming in at $83.44 million. AngioDynamics reported sales of $85.41 million in the same quarter last year, which would suggest a negative year over year growth rate of 2.4%. The company is expected to issue its next quarterly earnings results on Thursday, September 27th.
On average, analysts expect that AngioDynamics will report full year sales of $347.64 million for the current fiscal year, with estimates ranging from $345.00 million to $350.27 million. For the next year, analysts anticipate that the company will post sales of $354.19 million per share, with estimates ranging from $350.30 million to $358.08 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, July 11th. The medical instruments supplier reported $0.20 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.01). AngioDynamics had a net margin of 4.74% and a return on equity of 5.21%. The company had revenue of $88.30 million during the quarter, compared to analyst estimates of $89.02 million. The company’s quarterly revenue was up 1.6% compared to the same quarter last year.
ANGO has been the subject of several recent analyst reports. BidaskClub cut shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 1st. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday. Canaccord Genuity reaffirmed a “hold” rating and set a $20.00 price objective on shares of AngioDynamics in a research report on Thursday, July 12th. Finally, Raymond James cut shares of AngioDynamics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 11th. Five investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $18.44.
ANGO stock opened at $23.99 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.08 and a current ratio of 2.93. AngioDynamics has a 52 week low of $15.16 and a 52 week high of $24.24. The stock has a market capitalization of $875.35 million, a P/E ratio of 32.34 and a beta of 0.93.
Several hedge funds have recently bought and sold shares of ANGO. JPMorgan Chase & Co. lifted its holdings in shares of AngioDynamics by 958.2% in the first quarter. JPMorgan Chase & Co. now owns 895,414 shares of the medical instruments supplier’s stock worth $15,447,000 after acquiring an additional 810,794 shares during the last quarter. Tributary Capital Management LLC bought a new position in shares of AngioDynamics in the second quarter worth about $9,681,000. Segall Bryant & Hamill LLC lifted its holdings in shares of AngioDynamics by 141.1% in the first quarter. Segall Bryant & Hamill LLC now owns 651,782 shares of the medical instruments supplier’s stock worth $11,243,000 after acquiring an additional 381,497 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of AngioDynamics by 7.3% in the second quarter. BlackRock Inc. now owns 5,478,788 shares of the medical instruments supplier’s stock worth $121,848,000 after acquiring an additional 374,834 shares during the last quarter. Finally, Heartland Advisors Inc. bought a new position in shares of AngioDynamics in the first quarter worth about $5,990,000. 98.18% of the stock is owned by hedge funds and other institutional investors.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Article: Trading Strategy Examples and Plans
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.